MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications Life Science Investing
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA Life Science Investing
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. in a Transaction Valued at Over $100 Million Life Science Investing
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery Life Science Investing
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy Ahead of Planned BLA Submission for U.S. Accelerated Approval Life Science Investing
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech Life Science Investing
CSL Canada Announces First Canadian Patient Receives HEMGENIX® Hemophilia B Gene Therapy in Ontario, Canada Life Science Investing
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease Life Science Investing
